US-based UVLrx Therapeutics has obtained CE mark approval for its 1500 multi-wavelength, intravenous light therapy system, allowing the firm to market the device in the European Union.
Through using the firm’s patent pending Dry Light Adapter and a standard I.V. catheter, the UVLrx 1500 system avoids the need for removal of blood from the body.
The system is a LED-based medical device, which administers multiple wavelengths through a peripheral I.V. catheter to the passing blood supply.
It also enables the first intravenous and concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths.
The CE mark approval has been granted for the indications, including reduction of pain and inflammation, reduction of pathogens in the blood and immune system modulation.
Other indications include improved ATP synthesis and wound healing, as well as improved blood oxygen transport and circulation.
UVLrx Therapeutics CEO and president Michael Harter said: "We are pleased to have received the CE mark and are bringing the UVLrx 1500 System to the European market.
"The breadth of indications covered by our CE points to a bright future for this treatment and for the patients who will benefit from the technology."
The hospitals, outpatient surgery centers and private practice physicians can use the UVLrx treatment system for a variety of indications and conditions.
Image: UVLrx Therapeutics’ intravenous light therapy system. Photo: courtesy of Business Wire.